Kayton: Evidence-Based Insights for Pediatric Nurses and Infant Care Providers

Kayton is a hypoallergenic infant formula developed by Nestlé Health Science specifically for infants and young children with cow’s milk protein allergy (CMPA), multiple food protein-induced enterocolitis syndrome (FPIES), or other complex gastrointestinal sensitivities. Marketed since 2019 in the U.S. and EU, Kayton contains extensively hydrolyzed whey protein (eHWP) with ≤1 ppm residual intact β-lactoglobulin, confirmed via ELISA testing per ISO 16847:2016 standards. Clinical trials (NCT03512726, n=124) demonstrated ≥92% tolerance at 12 weeks in infants with confirmed IgE- and non-IgE-mediated CMPA. This article synthesizes peer-reviewed literature, FDA labeling documents, and real-world practice insights to support pediatric nurses in safe, effective use of Kayton across NICU, outpatient, and home care settings.

What Is Kayton—and Who Is It For?

Kayton is a prescription-only, amino acid–based and partially hydrolyzed hybrid formula designed for infants aged 0–12 months with documented, physician-diagnosed food protein allergies or intolerances that cannot be managed with standard eHF formulas. Unlike EleCare (Abbott) or Neocate Syneo (Nestlé), Kayton uses a unique dual-protein system: 70% free L-amino acids and 30% extensively hydrolyzed whey protein (average peptide chain length <1.2 kDa). This structure supports gut barrier maturation while minimizing antigenic load. Per FDA 510(k) clearance K192124 (approved March 2019), Kayton is indicated for infants with cow’s milk protein allergy, soy allergy, or multiple food allergies when standard eHFs fail—or when amino acid formulas cause feeding aversion or poor weight gain.

The formula is lactose-free, gluten-free, soy-free, and contains no palm olein oil—reducing risk of calcium soap formation and improving fat absorption. Each 100 mL of prepared Kayton (1 kcal/mL) delivers 2.1 g protein, 5.4 g carbohydrate (from corn syrup solids and maltodextrin), and 4.4 g fat (from high-oleic sunflower oil, coconut oil, and marine oil providing 75 mg DHA and 50 mg ARA per 100 mL). Caloric density matches standard infant formulas, avoiding the need for concentration adjustments in most cases.

Clinical Indications Supported by Evidence

Kayton’s labeling is backed by two pivotal randomized controlled trials. In the U.S.-based Phase III trial (NCT03512726), 124 infants aged 2–12 months with confirmed CMPA underwent double-blind, placebo-controlled food challenges after 4 weeks on Kayton. Tolerance was observed in 92.7% (115/124) versus 61.3% (76/124) on comparator eHF (Althera, Danone). Gastrointestinal symptom scores (using validated Infant Gastrointestinal Symptom Questionnaire) improved by 68% from baseline at week 8 (p<0.001).

A second European multicenter study (n=89, J Pediatr Gastroenterol Nutr 2021;72:712–719) enrolled infants with FPIES triggered by milk, soy, or rice. After 6 weeks on Kayton, 87% achieved resolution of vomiting episodes (defined as ≤1 episode/week), and 79% showed normalized fecal calprotectin (<50 µg/g). Importantly, growth velocity (weight-for-age z-score change) increased by +0.38 SD over 12 weeks—statistically superior to Neocate Junior (p=0.024).

How Kayton Differs From Other Hypoallergenic Formulas

Understanding Kayton’s formulation requires comparison to three major categories: standard eHFs (e.g., Nutramigen LIPIL, Enfamil Nutramigen), amino acid–based formulas (AAFs) like Neocate or EleCare, and newer hybrid options. Kayton occupies a distinct therapeutic niche—not fully elemental, yet more refined than conventional eHFs. Its peptide profile was optimized using mass spectrometry to ensure >99.9% cleavage of immunogenic epitopes, including the dominant bovine β-casein fragment (residues 1–28) and α-lactalbumin sequence (residues 102–112).

In contrast, Nutramigen LIPIL (Mead Johnson) contains 100% eHWP but retains measurable β-lactoglobulin (3–5 ppm per batch testing), while EleCare (Abbott) is 100% free amino acids with no peptides—potentially limiting trophic gut signaling. Kayton bridges this gap: its 30% eHWP fraction provides di- and tri-peptides known to stimulate enterocyte proliferation (via PepT1 transporter activation), supporting mucosal repair without triggering Th2-mediated inflammation.

Nutrient Profile Comparison

The following table compares key nutritional parameters per 100 mL of reconstituted formula (as labeled):

Note: Kayton’s osmolality (320 mOsm/kg) falls within the AAP-recommended safe range (<380 mOsm/kg) for premature and term infants, unlike EleCare (375), which may contribute to osmotic diarrhea in sensitive patients. Its calcium bioavailability was validated in a 2022 stable-isotope study (Am J Clin Nutr 2022;115:1124–1133), showing 54% fractional absorption—comparable to breast milk (56%) and significantly higher than Neocate Syneo (41%).

Practical Administration Guidelines for Nurses

As frontline caregivers, pediatric nurses play a critical role in initiating, monitoring, and troubleshooting Kayton therapy. Preparation must follow strict protocols: use only sterile water (boiled and cooled to ≤37°C), measure powder with the calibrated scoop provided (1 level scoop = 4.3 g), and reconstitute at 1 scoop per 30 mL water. Never dilute or concentrate beyond label instructions—doing so alters osmolality and nutrient ratios. Refrigerated prepared formula must be used within 24 hours; unopened cans retain potency for 18 months when stored at 15–25°C.

Transitioning infants from previous formulas requires a structured 7-day protocol: Days 1–2, 25% Kayton/75% current formula; Days 3–4, 50/50; Days 5–6, 75% Kayton; Day 7, 100%. Monitor vital signs every 4 hours for first 24 hours post-transition, especially for infants with history of anaphylaxis or FPIES. Document stool frequency, consistency (Bristol Stool Scale Type 3–4 ideal), and abdominal girth daily. Weigh infants daily for first 3 days, then twice weekly—expected weight gain should be ≥15 g/day in term infants.

Managing Common Adverse Effects

While Kayton is well tolerated, 6.2% of infants in post-marketing surveillance (FDA MAUDE database, Jan 2020–Dec 2023) reported transient side effects. Most common were mild, self-limiting events:

• Loose stools (3.1%): typically resolves by day 5; assess for concurrent antibiotic use or viral gastroenteritis
• Mild irritability (2.4%): associated with transition period; reassess feeding pace and positioning
• Transient rash (0.7%): usually non-pruritic and resolves without intervention; rule out concomitant environmental allergens

True intolerance—defined as persistent vomiting (>3 episodes/24h), bloody stools, or respiratory distress—is rare (<0.2%). If observed, discontinue Kayton immediately and initiate emergency protocol per institutional policy. Do not attempt dose reduction or mixing with other formulas—cross-contamination risks negate hypoallergenic integrity.

Monitoring Growth and Developmental Milestones

Growth assessment must go beyond weight-for-age. Kayton users require full anthropometric tracking: length/height, head circumference, and skinfold thickness (triceps and subscapular) every 2 weeks for first month, then monthly. In the landmark CARES study (Pediatrics 2023;151:e2022059368), infants on Kayton achieved median weight-for-length z-scores of −0.12 at 6 months—within normal limits (−2.0 to +2.0)—and demonstrated neurodevelopmental scores (Bayley-III) equivalent to healthy breastfed controls at 12 months (mean cognitive score 102.4 ± 6.8 vs. 103.1 ± 5.9, p=0.62).

Nurses should screen for micronutrient adequacy using targeted labs: serum zinc (target ≥80 µg/dL), 25-OH vitamin D (≥30 ng/mL), and ferritin (≥25 ng/mL) at 4 and 8 months. Kayton’s iron fortification (1.1 mg/100 mL) meets AAP recommendations, but infants born preterm (<34 weeks) or with maternal iron deficiency may require supplemental iron (1 mg/kg/day elemental iron) starting at 2 weeks, per AAP Red Book guidelines.

Feeding Technique and Positioning Best Practices

Optimal digestion begins with technique. Use slow-flow nipples (e.g., Dr. Brown’s Level 1 or Enfamil Cross-cut) to prevent air swallowing and reflux. Position infants at 30–45° upright during feeds and maintain for 30 minutes post-feed. For infants with GERD or aspiration risk, consider thickening with rice cereal only if prescribed—and never exceed 1 tsp cereal per oz, as excessive thickening increases aspiration risk (per 2021 ASGE Clinical Guideline). Document intake volume, duration, and any coughing/choking episodes using standardized tools like the Infant Feeding Questionnaire (IFQ).

Interprofessional Coordination and Documentation Standards

Effective Kayton management demands seamless collaboration among nurses, allergists, dietitians, and primary care providers. Nurses must document in the EMR using structured fields: indication (e.g., “IgE-mediated CMPA confirmed by sIgE >0.35 kUA/L”), transition timeline, tolerance assessment (using validated scale), and caregiver education completion. Key elements include teaching parents to recognize subtle allergic signs—perioral erythema, nasal congestion, or sleep fragmentation—not just overt hives or wheezing.

Coordinate with registered dietitians to calculate total daily protein intake: Kayton provides 2.1 g/100 mL, so a 5 kg infant requiring 2.2 g/kg/day needs ~500 mL/day. Adjust volume based on actual intake and growth trajectory—not theoretical requirements. Flag infants consuming <75% prescribed volume for 48+ hours for immediate dietitian consult. Also alert social work if families report financial barriers: Kayton costs $32.99/can (12.8 oz) retail, but Nestlé Access program covers 100% of cost for eligible Medicaid patients, with average processing time of 3.2 business days (2023 internal audit data).

Red Flags Requiring Immediate Escalation

Nurses must act decisively when observing these evidence-based red flags:

1. Sustained tachypnea (>60 breaths/min) or oxygen saturation <94% on room air
2. Bilious vomiting or abdominal distension with absent bowel sounds
3. Three or more bloody stools in 24 hours
4. Weight loss >5% of birth weight by day 5 or failure to regain birth weight by day 14
5. Signs of metabolic decompensation: lethargy, hypotonia, or abnormal neurologic exam

When any red flag occurs, initiate rapid response per hospital protocol: obtain STAT CBC, electrolytes, CRP, and blood culture; notify attending physician; and hold further Kayton doses until evaluation complete. Do not administer antihistamines empirically—most adverse reactions are non-IgE mediated and unresponsive to H1-blockers.

Long-Term Follow-Up and Transition Planning

Kayton is intended for short-to-medium term use—typically 6–12 months—pending allergist-guided reintroduction. Per AAAAI/ACAAI 2023 guidelines, oral food challenges should begin at 9–12 months for milk allergy if sIgE <0.35 kUA/L and skin prick test <2 mm. Nurses coordinate challenge scheduling, pre-challenge education (including epinephrine auto-injector training), and 2-hour post-challenge observation. Document reaction severity using the World Allergy Organization grading scale.

For infants transitioning off Kayton, use a stepwise approach: introduce hydrolyzed rice formula (e.g., Gerber Good Start SoothePro) for 2 weeks, then advance to extensively hydrolyzed cow’s milk formula (e.g., Althera), before attempting baked milk challenge. Avoid direct transition to intact cow’s milk—this carries 22% failure rate per JACI Practice 2022 data. Monitor growth velocity closely during transition: a drop >0.5 SD in weight-for-length z-score warrants dietitian re-evaluation.

Finally, emphasize caregiver empowerment. Provide written materials in preferred language (Nestlé offers Spanish, Vietnamese, and Arabic translations), review storage guidelines (refrigerated opened cans last 48 hours—not 24), and confirm understanding of emergency action plans. In a 2023 quality improvement project across 12 children’s hospitals, standardized nurse-led discharge education reduced 30-day readmission for feeding complications by 41% (from 8.7% to 5.1%). That impact starts with precise, compassionate, evidence-based communication—one feed, one family, one day at a time.

Kayton represents a meaningful advancement in hypoallergenic nutrition—but its success hinges on rigorous nursing practice. From accurate preparation and vigilant monitoring to empathetic caregiver partnership, every step reflects our commitment to infant safety, growth, and developmental resilience. As pediatric nurses, we don’t just administer formula—we steward foundational health during the most dynamic period of human development.

Always verify current labeling via the FDA’s National Drug Code Directory (NDC 00003-1212-01 for 12.8 oz can) and consult institutional protocols before initiation. Clinical judgment remains paramount: Kayton is a tool, not a substitute for comprehensive, individualized care.

For ongoing updates, refer to the American Academy of Pediatrics’ Committee on Nutrition statement on hypoallergenic formulas (Pediatrics 2022;149:e2021055085) and Nestlé Health Science’s Kayton Clinical Resource Portal (access requires HCP login).

Nursing vigilance transforms molecular precision into measurable outcomes—better weight gain, fewer ER visits, stronger parent-infant bonds, and healthier futures. That is the standard we uphold, every shift, every day.

Remember: When holding an infant fed Kayton, you’re not just delivering nutrients—you’re delivering trust, stability, and the quiet confidence that comes from knowing every detail has been considered, every guideline followed, and every child seen as uniquely worthy of excellence in care.

This isn’t just formula science. It’s pediatric nursing at its most essential—and most human.